

IN THE UNITED STATES PATENT AND TRADEMARK OFFICERECEIVED
CENTRAL FAX CENTER

FEB 03 2006

Application of: Dasseux *et al.* Confirmation No.: 4097
Serial No.: 10/801,897 Art Unit: 1654
Filed: March 15, 2004 Examiner: Jeffrey E. Russel
For: APOLIPOPROTEIN A-I Attorney Docket No.: 9196-032-999
AGONISTS AND THEIR USE TO (PC20701C)
TREAT DYSLIPIDEMIC
DISORDERS

REPLY AND AMENDMENT UNDER 37 CFR § 1.111 AND 1.121

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The enclosed Reply and Amendment under 37 C.F.R. § 1.111 and 1.121 is in response to the Office Action dated August 3, 2005, for the above-identified patent application. The period for response to this Office Action has been extended to February 3, 2006, pursuant to Applicants' Petition for Extension of Time filed herewith.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 8 of this paper.

Also enclosed are:

a **Petition for Extension of Time** from November 3, 2005, to and including February 3, 2006, for responding to the Office Action;

Three Terminal Disclaimers;

a **Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address Form, and**

Substitute Paper Copy of Sequence Listing.